Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making
Oncology Research · 2026
DOI: 10.32604/or.2026.072992 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Paolo Maione und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, S.G. Moscati Hospital, Avellino, 83100, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Lung Neoplasms, Lactams, Macrocyclic. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino, 83100, Italy.
- Division of Medical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Napoli, 80121, Italy.
Zitieren
APA
Maione, P., Palma, V., & Gridelli, C. (2026). Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. Oncology Research. https://doi.org/10.32604/or.2026.072992
Vancouver
Maione P, Palma V, Gridelli C. Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. Oncology Research. 2026. doi:10.32604/or.2026.072992
BibTeX
@article{Maione2026,
author = {Maione, Paolo and Palma, Valentina and Gridelli, Cesare},
title = {Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.072992}
}
EUVIMED